Wolfe Research analyst Alexandria Hammond initiated coverage of Amgen (AMGN) with a Peer Perform rating. With the antibody backbone, the firm ...

2 Dividend Stocks to Buy Hand Over Fist in November was originally published by The Motley Fool Their recent issues are ...

Key Takeaways Amgen refutes in a press release that its trial obesity drug, MariTide, may cause bone loss density. Amgen's ...

Analysts have set 12-month price targets for Amgen, revealing an average target of $349.0, a high estimate of $405.00, and a ...

Several key players are shaping the global pruritus therapeutics market. Companies such as Allergan Inc., Amgen Inc., Astellas Pharma Inc., CARA Therapeutics, Novartis AG, and Teva Pharmaceutical ...

Amgen and AstraZeneca today announced positive top-line results from the Phase 3 WAYPOINT trial in patients with chronic rhinosinusitis with nasal polyps (CRSwNP [nasal polyps]). The trial ...

Discover why Amgen is a reliable wealth compounder with strong Q3 results, a promising pipeline, debt reduction, and ...

Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. The company’s principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic ...

Sales for Lumakras and Blincyto in particular soared during the third quarter as the firm's overall revenues climbed 23 percent year over year.

Amgen ( AMGN 1.68%), a leader in biotechnology, released its third-quarter 2024 financial results on Oct. 30. The company ...

While Amgen’s third-quarter financial results on Wednesday were “somewhat uneventful,” investors continue to be focused on ...

Total product revenues increased ... interested in the progress of Amgen’s GLP-1 receptor candidate, MariTide (maridebart cafraglutide), for obesity. Top-line 52-week data from the phase II ...